Navigation Links
Bacterial Protein Shows Promise in Treating Intestinal Parasites

Scientists at the University of California, San Diego and Yale University have discovered that a natural protein produced by Bacillus thuringiensis, a bacterium sprayed// on crops by organic farmers to reduce insect damage, is highly effective at treating hookworm infections in laboratory animals.

Their discovery, detailed in this week’s early online edition of the Proceedings of the National Academy of Sciences, could pave the way for the development of more effective treatments for hookworm and other soil-transmitted nematode infections, which are a major global health problem in developing countries. Many of the nearly two billion people worldwide infected with these intestinal parasites are children, who are at particular risk for anemia, malnutrition and delayed growth.

The UCSD-Yale team found that a protein produced by the bacterium Bacillus thuringiensis, or Bt, given orally to laboratory hamsters infected with hookworms was as effective in eliminating the parasites, curing anemia and restoring weight gain in the hamsters as mebendazole, one of the drugs currently recommended to treat infections in humans. The scientists also discovered that this protein, called Cry5B, targets both developing, or larval, stages and adult parasites, as well as impairs the excretion of eggs by female worms.

Hookworms cause anemia by attaching to the intestine and feeding on their host’s blood and nutrients, causing anemia and weight loss. The researchers said in their paper that because this naturally-produced protein is safe to humans and other vertebrates and can be produced inexpensively in large quantities, it has the potential to substantially improve this global health problem.

“Our ability to control parasitic nematode infections with chemotherapy on a global scale is dependent on the availability of medicines that are safe, effective, and inexpensive to manufacture,” said Michael Cappello, one of two principal authors of t he study and a professor of pediatrics and epidemiology & public health at Yale School of Medicine. “We believe that Bt crystal proteins not only meet, but exceed these essential criteria.”

The discovery is particularly relevant to global health, because of concerns about the potential emergence of resistance in human intestinal nematodes to currently available medicines.

“There are only a few new agents under development for the treatment of hookworm and other intestinal parasite infections," said Raffi Aroian, an associate professor of biology at UCSD and co-principal author of the study. "Crystal toxins are safe to humans, mammals and other vertebrates. And it might be possible to improve the efficacy of current treatments by giving a drug like mebendazole and Cry5B simultaneously.”

Other authors of the study are Richard Bungiro and Lisa Harrison of the Yale medical school and Larry Bischof, Joel Griffitts and Brad Barrows of UCSD.

Aroian and his UCSD colleagues discovered five years ago that the roundworm C. elegans and other nematodes are susceptible to the effects of Cry5B, then known primarily as an insecticide. The toxin forms tiny holes in the membranes of the cells of nematodes and insects. However, since the toxin can’t bind to the cells of mammals or other vertebrates, Cry proteins can’t hurt humans.

“Crystal proteins had been used for decades to kill insects by organic farmers who sprayed their crops with Bt,” said Aroian. “Until now, however, no one has used a purified Cry protein to treat a parasitic nematode.”

Aroian met Cappello, a pediatric infectious diseases specialist who studies hookworm, at a meeting of the Burroughs-Wellcome Fund and decided to collaborate on a project to see if crystal proteins could be effective against hookworm infections. Three years ago, Aroian and his colleagues purified Cry5B toxin and sent it to Cappello, who then tested the compound in a laboratory model of hookworm infection.

“It worked on the first day,” said Aroian. “Laboratory animals treated with Cry5B survived a lethal hookworm infection, and showed no side effects from the medication.”

Colleagues in Cappello’s lab then carried out additional experiments that demonstrated that Cry5B was comparable to mebendazole for treating hookworm infection in laboratory animals. Additional studies also determined which life cycle stages of the parasite were most susceptible to Cry5B and at what concentrations.

“These experiments confirmed that the mechanism of action of Cry5B in Ancylostoma hookworms appears to be identical to that for other nematodes, including C. elegans,” said Cappello. “This suggests that crystal proteins will likely have activity against a broad range of nematodes, and could be used to treat children who are often infected with multiple intestinal parasites. Studies are underway to fully define the spectrum of activity of Cry5B as part of its preclinical development as a human therapeutic.”

ource-Newswise
SRM
'"/>




Related medicine news :

1. Bacterial discovery may help CF patients
2. Cure for Bacterial Meningitis
3. Molecule That Aids Bacterial Infections Identified
4. Bacterial Photographs Created By Student Scientists!
5. Bacterial infestation in food very critical!
6. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
7. Children Of Smoking Parents Face Increased Risk Of Bacterial Infection
8. Petting Zoos Can Lead To Bacterial Infection And Illness
9. Treatment of Bacterial Infection Paves the Way to Treat CF Infection
10. ‘Biofilms’-Clumped Bacterial Slime Cause Ear Infectin
11. PGLYRP Proteins Prevent Bacterial Infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: